Related Experiment Videos
Progressive multifocal leukoencephalopathy complicating treatment for Wegener's granulomatosis
1Department of Neurology, Johns Hopkins Hospital, Baltimore, MD, USA.
The Journal of Rheumatology
|August 1, 1995
Abstract:
We describe a man treated with cyclophosphamide and prednisone for Wegener's granulomatosis who developed biopsy proven progressive multifocal leukoencephalopathy (PML). Upon discontinuation of immunosuppression he made a dramatic recovery. As immunosuppressant use is increasing we draw attention to this potentially fatal, but reversible neurologic disease.
Insights
A patient with Wegener's granulomatosis developed progressive multifocal leukoencephalopathy (PML) after immunosuppressive therapy. Discontinuing treatment led to a significant recovery, highlighting PML as a reversible neurologic condition.
Area of Science:
- Neurology
- Immunology
- Infectious Diseases
Background:
- Wegener's granulomatosis is a systemic vasculitis.
- Immunosuppressive agents like cyclophosphamide and prednisone are used for treatment.
- Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease.
Observation:
- A patient with Wegener's granulomatosis developed neurological symptoms.
- Biopsy confirmed progressive multifocal leukoencephalopathy (PML).
- The patient was undergoing treatment with cyclophosphamide and prednisone.
Findings:
- Discontinuation of immunosuppressive therapy resulted in a dramatic recovery.
- This suggests a direct link between immunosuppression and PML development.
- PML is a potentially fatal but reversible neurologic disease.
Implications:
- Increased use of immunosuppressants necessitates awareness of PML.
- Early diagnosis and withdrawal of immunosuppression are crucial for patient outcomes.
- This case highlights the importance of monitoring for opportunistic infections during immunosuppressive therapy.